ProQR Therapeutics (PRQR) Total Non-Current Liabilities (2021 - 2025)

ProQR Therapeutics (PRQR) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $36.0 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 16.77% to $36.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.0 million through Dec 2025, down 16.77% year-over-year, with the annual reading at $36.0 million for FY2025, 16.77% down from the prior year.
  • Total Non-Current Liabilities hit $36.0 million in Q4 2025 for ProQR Therapeutics, down from $43.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $85.3 million in Q4 2022 to a low of $36.0 million in Q4 2025.
  • Historically, Total Non-Current Liabilities has averaged $62.1 million across 5 years, with a median of $67.0 million in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: increased 8.51% in 2022 and later tumbled 35.43% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $78.7 million in 2021, then rose by 8.51% to $85.3 million in 2022, then decreased by 21.47% to $67.0 million in 2023, then crashed by 35.43% to $43.3 million in 2024, then decreased by 16.77% to $36.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for PRQR at $36.0 million in Q4 2025, $43.3 million in Q4 2024, and $67.0 million in Q4 2023.